The extreme dilution (2.8x share count expansion) will likely pressure the stock price toward the $1.00 offering price. Monitor for over-allotment exercise and potential secondary selling. The warrants add further overhang.
Price Chart
Executive Summary
Rein Therapeutics closed a massively dilutive underwritten public offering of 50M shares at $1.00 per share, raising ~$46.1M in net proceeds. The offering increases the share count by ~2.8x versus pre-offering outstanding, severely diluting existing shareholders. Additionally, the company issued warrants to the underwriter (1.725M shares at $1.50) and to Bios entities (3M shares at $1.00), adding further overhang.
Key Facts
- Closed offering of 50,000,000 shares of common stock at $1.00 per share for gross proceeds of $50M.
- Net proceeds approximately $46.1M after underwriting discounts and expenses.
- Underwriter granted 45-day option to purchase up to 7,500,000 additional shares (15% over-allotment).
- Underwriter received warrants for 3% of shares sold (1,725,000 shares) at $1.50 per share, exercisable for 5 years.
- Bios entities received warrants to purchase 3,000,000 shares at $1.00 per share in exchange for deferring preferred stock conversion and lock-up until April 2029.
- Proceeds to fund Phase 2 trial of LTI-03 in IPF and extend runway into 2028.
Financial Impact
Massive dilution: offering adds ~50M shares (potentially 57.5M with over-allotment) versus pre-offering ~18M implied by $29M market cap at $1.355 pre-offer price. Net proceeds $46.1M provide capital but at extreme cost to existing holders.
Risk Factors
- Further dilution from over-allotment option (up to 7.5M additional shares).
- Potential selling pressure from warrant exercises (4.725M shares total).
- Clinical trial execution risk for LTI-03; failure could render the raised capital insufficient.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-204006 |
| Document: d168655d8k.htm | 0001193125-26-204006 |
| Document: d168655dex991.htm | 0001193125-26-204006 |
| Document: d168655dex51.htm | 0001193125-26-204006 |
| Document: 0001193125-26-204006-index-headers.html | 0001193125-26-204006 |
| Document: 0001193125-26-204006-index.html | 0001193125-26-204006 |
| Document: 0001193125-26-204006.txt | 0001193125-26-204006 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 7w ago | Press Release | $0.8891 | awaiting T+60 | — | $0.6947 (−21.86%) |
Aug 14, 2026 10w ago | Press Release | $0.8060 | awaiting T+60 | — | $0.6947 (−13.81%) |
Jul 21, 2026 14w ago | Press Release | $0.8948 $0.7546 | ▼ −15.67% | ▼ −19.64% | $0.6947 (−22.36%) |
Jun 8, 2026 20w ago | DEFA14A | $0.9487 $0.7527 | ▼ −20.66% | ▼ −23.71% | $0.6947 (−26.77%) |
May 4, 2026 25w ago | 8-K | $1.02 $0.7680 | ▲ +24.71% | ▲ +27.45% | $0.6947 (+31.89%) |
May 4, 2026 25w ago | 424B5 | $1.02 $0.7580 | ▲ +25.69% | ▲ +27.54% | $0.6947 (+31.89%) |
May 1, 2026 25w ago | Press Release | $1.03 $0.7818 | ▲ +24.10% | ▲ +27.17% | $0.6947 (+32.55%) |
Apr 29, 2026 25w ago | Press Release | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.6947 (−45.51%) |
Apr 28, 2026 25w ago | S-1 | $1.28 $0.7913 | ▼ −37.94% | ▼ −42.05% | $0.6947 (−45.51%) |
Apr 27, 2026 26w ago | 10-K/A | $1.49 $0.8400 | ▼ −43.62% | ▼ −48.40% | $0.6947 (−53.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers